Population pharmacokinetics of antibacterial agents in the older population: a literature review

References

• Calder PC, Ortega EF, Meydani SN, et al. Nutrition, immunosenescence, and infectious disease: an overview of the scientific evidence on micronutrients and on modulation of the gut microbiota. Adv In Nutr (Bethesda, MD). 2022 Oct 2;13(5):S1–s26. doi: 10.1093/advances/nmac052
   PubMed Web of Science ®Google Scholar
• Norman DC. Clinical features of infection in older adults. Clin Geriatr Med. 2016 Aug;32(3):433–441. doi: 10.1016/j.cger.2016.02.005
   PubMed Web of Science ®Google Scholar
• Dumic I, Nordin T, Jecmenica M, et al. Gastrointestinal tract disorders in older age. Can J Gastroenterol Hepatol. 2019;2019:6757524. doi: 10.1155/2019/6757524
   PubMed Web of Science ®Google Scholar
• Soenen S, Rayner CK, Jones KL, et al. The ageing gastrointestinal tract. Current opinion in clinical nutrition and metabolic care. Current Opin Clin Nutr Metab Care. 2016 Jan;19(1):12–18.
   PubMed Web of Science ®Google Scholar
• Pereira JM, Paiva JA. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol. 2013 Feb 1;8(1):25–38.
   PubMedGoogle Scholar
• Ponti F, Santoro A, Mercatelli D, et al. Aging and imaging assessment of body composition: from fat to facts. Front Endocrinol. 2019;10:861. doi: 10.3389/fendo.2019.00861
   PubMed Web of Science ®Google Scholar
• Wynne H. Drug metabolism and ageing. J Br Menopause. 2005 Jun;11(2):51–56. doi: 10.1258/136218005775544589
   PubMedGoogle Scholar
• Le Couteur DG, Fraser R, Hilmer S, et al. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet. 2005;44(2):187–200. doi: 10.2165/00003088-200544020-00004
   PubMed Web of Science ®Google Scholar
• Bellanti F, Vendemiale G. The aging liver: redox Biology and liver regeneration. Antioxid Redox Signaling. 2021 Oct 1;35(10):832–847.
   PubMed Web of Science ®Google Scholar
• Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Advances in chronic kidney disease. Adv Chronic Kidney Dis. 2016 Jan;23(1):19–28. doi: 10.1053/j.ackd.2015.08.004
   PubMed Web of Science ®Google Scholar
• Musso CG, Oreopoulos DG. Aging and physiological changes of the kidneys including changes in glomerular filtration rate. Nephron Physiology. 2011;119 Suppl 1(Suppl. 1):1–5. doi: 10.1159/000328010
   Google Scholar
• Edwards B, Milne K, Lawes T, et al. Is vancomycin MIC “creep” method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol. 2012 Feb;50(2):318–325.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44(10):1009–1034. doi: 10.2165/00003088-200544100-00002
   PubMed Web of Science ®Google Scholar
• Zhou Y, Gao F, Chen C, et al. Development of a Population pharmacokinetic model of vancomycin and its application in Chinese geriatric patients with pulmonary infections. Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):361–370.
   PubMed Web of Science ®Google Scholar
• Bourguignon L, Cazaubon Y, Debeurme G, et al. Pharmacokinetics of vancomycin in elderly patients aged over 80 years. Antimicrob Agents Chemother. 2016 Aug;60(8):4563–4567.
   PubMed Web of Science ®Google Scholar
• Glatard A, Bourguignon L, Jelliffe RW, et al. Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients. Antimicrobial agents and chemotherapy. Antimicrob Agents Chemother. 2015;59(6):2986–2994. doi: 10.1128/AAC.04132-14
   PubMed Web of Science ®Google Scholar
• Bang JY, Kang HI, Lee HJ, et al. Development of a new pharmacokinetic model for target-concentration controlled infusion of vancomycin in critically ill patients. Clinical and experimental pharmacology & physiology. Clin Exp Pharmacol Physiol. 2022 Feb;49(2):202–211. doi: 10.1111/1440-1681.13597
   PubMed Web of Science ®Google Scholar
• Medellín-Garibay SE, Ortiz-Martín B, Rueda-Naharro A, et al. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. J Antimicrob Chemother. 2016 Feb;71(2):471–479.
   PubMed Web of Science ®Google Scholar
• Kovacevic T, Miljkovic B, Kovacevic P, et al. Population pharmacokinetic model of vancomycin based on therapeutic drug monitoring data in critically ill septic patients. J Crit Care. 2020 Feb;55:116–121.
   PubMed Web of Science ®Google Scholar
• Oda K, Jono H, Kamohara H, et al. Development of vancomycin dose individualization strategy by bayesian prediction in patients receiving continuous renal replacement therapy. Pharm Res. 2020 May 28;37(6):108. doi: 10.1007/s11095-020-02820-0
   PubMed Web of Science ®Google Scholar
• Kanji S, Roberts JA, Xie J, et al. Vancomycin Population pharmacokinetics in critically ill adults during sustained low-efficiency dialysis. Clin Pharmacokinet. 2020 Mar;59(3):327–334.
   PubMed Web of Science ®Google Scholar
• Westra N, Proost JH, Franssen CFM, et al. Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration. PLoS One. 2019;14(5):e0216801. doi: 10.1371/journal.pone.0216801
   PubMed Web of Science ®Google Scholar
• Hui K, Patel K, Nalder M, et al. Optimizing vancomycin dosage regimens in relation to high-flux haemodialysis. J Antimicrob Chemother. 2019 Jan 1;74(1):130–134. doi: 10.1093/jac/dky371
   PubMed Web of Science ®Google Scholar
• Goti V, Chaturvedula A, Fossler MJ, et al. Hospitalized patients with and without hemodialysis have markedly different vancomycin pharmacokinetics: a Population pharmacokinetic model-based analysis. Ther Drug Monit. 2018 Apr;40(2):212–221.
   PubMed Web of Science ®Google Scholar
• Economou CJP, Kielstein JT, Czock D, et al. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. Int J Antimicrob Agents. 2018 Aug;52(2):151–157.
   PubMed Web of Science ®Google Scholar
• Udy AA, Covajes C, Taccone FS, et al. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Int J Antimicrob Agents. 2013 Jun;41(6):564–568.
   PubMed Web of Science ®Google Scholar
• Lin Z, Chen DY, Zhu YW, et al. Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units. Sci Rep. 2021 Jan 29;11(1):2670. doi: 10.1038/s41598-021-82312-2
   PubMed Web of Science ®Google Scholar
• Masich AM, Kalaria SN, Gonzales JP, et al. Vancomycin pharmacokinetics in obese patients with sepsis or septic shock. Pharmacotherapy. 2020 Mar;40(3):211–220.
   PubMed Web of Science ®Google Scholar
• Jaisue S, Pongsakul C, D’Argenio DZ, et al. Population pharmacokinetic modeling of vancomycin in Thai patients with heterogeneous and unstable renal function. Ther Drug Monit. 2020 Dec;42(6):856–865.
   PubMed Web of Science ®Google Scholar
• Vu DH, Nguyen DA, Delattre IK, et al. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: population pharmacokinetic modelling and simulations for improved dosing schemes. Int J Antimicrob Agents. 2019 Dec;54(6):702–708.
   PubMed Web of Science ®Google Scholar
• Blassmann U, Hope W, Roehr AC, et al. CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. J Antimicrob Chemother. 2019 Apr 1;74(4):991–996. doi: 10.1093/jac/dky543
   PubMed Web of Science ®Google Scholar
• Abraham J, Sinnollareddy MG, Roberts MS, et al. Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis. Int J Antimicrob Agents. 2019 Feb;53(2):137–142.
   PubMed Web of Science ®Google Scholar
• Crass RL, Dunn R, Hong J, et al. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother. 2018 Nov 1;73(11):3081–3086. doi: 10.1093/jac/dky310
   PubMed Web of Science ®Google Scholar
• Medellín-Garibay SE, Romano-Moreno S, Tejedor-Prado P, et al. Influence of mechanical ventilation on the pharmacokinetics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2017 Dec;61(12): doi: 10.1128/AAC.01249-17
   PubMed Web of Science ®Google Scholar
• Chung JY, Jin SJ, Yoon JH, et al. Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci. 2013 Jan;28(1):48–54.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011 Jun;55(6):2704–2709.
   PubMed Web of Science ®Google Scholar
• Revilla N, Martín-Suárez A, Pérez MP, et al. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Brit J Clin Pharma. 2010 Aug;70(2):201–212.
   PubMed Web of Science ®Google Scholar
• Ji XW, Ji SM, He XR, et al. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacol Sin. 2018 Feb;39(2):286–293.
   PubMed Web of Science ®Google Scholar
• Purwonugroho TA, Chulavatnatol S, Preechagoon Y, et al. Population pharmacokinetics of vancomycin in Thai patients. ScientificWorldjournal. 2012;2012:762649. doi: 10.1100/2012/762649
   PubMedGoogle Scholar
• Roberts JA, Stove V, De Waele JJ, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI study. Int J Antimicrob Agents. 2014 May;43(5):423–430.
   PubMed Web of Science ®Google Scholar
• Ogami C, Tsuji Y, Muraki Y, et al. Population pharmacokinetics and pharmacodynamics of teicoplanin and C-Reactive protein in hospitalized patients with Gram-positive infections. Clinical Pharm in Drug Dev. 2020 Feb;9(2):175–188.
   PubMed Web of Science ®Google Scholar
• Kasai H, Tsuji Y, Hiraki Y, et al. Population pharmacokinetics of teicoplanin in hospitalized elderly patients using cystatin C as an indicator of renal function. J Infect Chemother. 2018 Apr;24(4):284–291.
   PubMed Web of Science ®Google Scholar
• Byrne CJ, Parton T, McWhinney B, et al. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. J Antimicrob Chemother. 2018 Apr 1;73(4):995–1003. doi: 10.1093/jac/dkx473
   PubMed Web of Science ®Google Scholar
• Soy D, López E, Ribas J. Teicoplanin population pharmacokinetic analysis in hospitalized patients. Ther Drug Monit. 2006 Dec;28(6):737–743. doi: 10.1097/01.ftd.0000249942.14145.ff
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clinical infectious diseases: an official publication of the infectious diseases Society of America. Clin Infect Dis. 2008 Sep 15;47(Suppl 1):S32–40.
   PubMed Web of Science ®Google Scholar
• Usman M, Frey OR, Hempel G. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function. Eur J Clin Pharmacol. 2017 Mar;73(3):333–342. doi: 10.1007/s00228-016-2172-4
   PubMed Web of Science ®Google Scholar
• O’Jeanson A, Larcher R, Le Souder C, et al. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):695–705.
   PubMed Web of Science ®Google Scholar
• Niibe Y, Suzuki T, Yamazaki S, et al. Population pharmacokinetic analysis of meropenem in critically ill patients with acute kidney injury treated with continuous hemodiafiltration. Ther Drug Monit. 2020 Aug;42(4):588–594.
   PubMed Web of Science ®Google Scholar
• Sjövall F, Alobaid AS, Wallis SC, et al. Maximally effective dosing regimens of meropenem in patients with septic shock. J Antimicrob Chemother. 2018 Jan 1;73(1):191–198. doi: 10.1093/jac/dkx330
   PubMed Web of Science ®Google Scholar
• Minichmayr IK, Roberts JA, Frey OR, et al. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. J Antimicrob Chemother. 2018 May 1;73(5):1330–1339. doi: 10.1093/jac/dkx526
   PubMed Web of Science ®Google Scholar
• Kim YK, Lee DH, Jeon J, et al. Population pharmacokinetic analysis of meropenem after intravenous infusion in Korean patients with acute infections. Clin Ther. 2018 Aug;40(8):1384–1395.
   PubMed Web of Science ®Google Scholar
• Braune S, König C, Roberts JA, et al. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study. Crit Care. 2018 Jan 30;22(1):25. doi: 10.1186/s13054-018-1940-1
   PubMedGoogle Scholar
• Crandon JL, Ariano RE, Zelenitsky SA, et al. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive care Med. 2011 Apr;37(4):632–638.
   PubMed Web of Science ®Google Scholar
• Doh K, Woo H, Hur J, et al. Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother. 2010 Nov;65(11):2428–2435.
   PubMed Web of Science ®Google Scholar
• Isla A, Rodríguez-Gascón A, Trocóniz IF, et al. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet. 2008;47(3):173–180. doi: 10.2165/00003088-200847030-00003
   PubMed Web of Science ®Google Scholar
• Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006 Oct;46(10):1171–1178.
   PubMed Web of Science ®Google Scholar
• Onichimowski D, Będźkowska A, Ziółkowski H, et al. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial. Pharmacol Rep. 2020 Jun;72(3):719–729.
   PubMed Web of Science ®Google Scholar
• Mattioli F, Fucile C, Del Bono V, et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016 Jul;72(7):839–848.
   PubMed Web of Science ®Google Scholar
• Ramon-Lopez A, Allen JM, Thomson AH, et al. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. J Antimicrob Chemother. 2015 Mar;70(3):882–890.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Depestel DCID:AOPOTIDSOA. Doripenem. Clin Infect Dis. 2009 Jul 15;49(2):291–298. doi: 10.1086/600036
   PubMed Web of Science ®Google Scholar
• Harada M, Inui N, Suda T, et al. Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia. Int J Antimicrob Agents. 2013 Aug;42(2):149–154.
   PubMed Web of Science ®Google Scholar
• Nonoshita K, Suzuki Y, Tanaka R, et al. Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit. Sci Rep. 2020 Dec 17;10(1):22148. doi: 10.1038/s41598-020-79076-6
   PubMed Web of Science ®Google Scholar
• Roberts JA, Udy AA, Bulitta JB, et al. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2014 Sep;69(9):2508–2516.
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim YK, Jin K, et al. Population pharmacokinetic analysis of doripenem after intravenous infusion in Korean patients with acute infections. Antimicrob Agents Chemother. 2017 May;61(5): doi: 10.1128/AAC.02185-16
   Web of Science ®Google Scholar
• Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med. 2013 Feb;41(2):489–495. doi: 10.1097/CCM.0b013e31826ab4c4
   PubMed Web of Science ®Google Scholar
• Nandy P, Samtani MN, Lin R. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother. 2010 Jun;54(6):2354–2359. doi: 10.1128/AAC.01649-09
   PubMed Web of Science ®Google Scholar
• Lipš M, Siller M, Strojil J, et al. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Int J Antimicrob Agents. 2014 Oct;44(4):358–362.
   PubMed Web of Science ®Google Scholar
• Li Z, Bai J, Wen A, et al. Pharmacokinetic and pharmacodynamic analysis of critically ill patients undergoing continuous renal replacement therapy with imipenem. Clin Ther. 2020 Aug;42(8):1564–1577.e8.
   PubMed Web of Science ®Google Scholar
• Suchánková H, Lipš M, Urbánek K, et al. Is continuous infusion of imipenem always the best choice? Int J Antimicrob Agents. 2017 Mar;49(3):348–354.
   PubMed Web of Science ®Google Scholar
• Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a ‘snapshot’ infectious diseases international research initiative (ID-IRI) survey. J Antimicrob Chemother. 2020 Nov 1;75(11):3386–3390. doi: 10.1093/jac/dkaa326
   PubMed Web of Science ®Google Scholar
• Remschmidt C, Schneider S, Meyer E, et al. Surveillance of antibiotic use and resistance in intensive care units (SARI). Dtsch Arztebl Int. 2017 Dec 15;114(50):858–865. doi: 10.3238/arztebl.2017.0858
   PubMed Web of Science ®Google Scholar
• Hemmersbach-Miller M, Balevic SJ, Winokur PL, et al. Population pharmacokinetics of piperacillin/tazobactam across the adult lifespan. Clin Pharmacokinet. 2023 Jan;62(1):127–139.
   PubMed Web of Science ®Google Scholar
• Wallenburg E, Ter Heine R, Schouten JA, et al. An Integral pharmacokinetic analysis of piperacillin and tazobactam in plasma and urine in critically ill patients. Clin Pharmacokinet. 2022 Jun;61(6):907–918.
   PubMed Web of Science ®Google Scholar
• Hahn J, Min KL, Kang S, et al. Population pharmacokinetics and dosing optimization of piperacillin-tazobactam in critically ill patients on extracorporeal membrane oxygenation and the influence of concomitant renal replacement therapy. Microbiol Spectr. 2021 Dec 22;9(3):e0063321. doi: 10.1128/Spectrum.00633-21
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Morandin E, Baraldo M, et al. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against enterobacterales and Pseudomonas aeruginosa. Int J Antimicrob Agents. 2021 Oct;58(4):106408.
   PubMed Web of Science ®Google Scholar
• Klastrup V, Thorsted A, Storgaard M, et al. Population pharmacokinetics of piperacillin following continuous infusion in critically ill patients and impact of renal function on target attainment. Antimicrob Agents Chemother. 2020 Jun 23;64(7): doi: 10.1128/AAC.02556-19
   PubMed Web of Science ®Google Scholar
• Ishihara N, Nishimura N, Ikawa K, et al. Population pharmacokinetic modeling and pharmacodynamic target attainment simulation of piperacillin/tazobactam for dosing optimization in late elderly patients with pneumonia. Antibiotics (Basel, Switzerland). 2020 Mar 6;9(3):113. doi: 10.3390/antibiotics9030113
   PubMed Web of Science ®Google Scholar
• Bue M, Sou T, Okkels ASL, et al. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy. Int J Infect Dis. 2020 Mar;92:133–140.
   PubMed Web of Science ®Google Scholar
• Dhaese SAM, Roberts JA, Carlier M, et al. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. Int J Antimicrob Agents. 2018 Apr;51(4):594–600.
   PubMed Web of Science ®Google Scholar
• Chen R, Qian Q, Sun MR, et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with nosocomial infections. Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):363–372.
   PubMed Web of Science ®Google Scholar
• Öbrink-Hansen K, Juul RV, Storgaard M, et al. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations? Antimicrob Agents Chemother. 2015 Nov;59(11):7018–7026.
   PubMed Web of Science ®Google Scholar
• Jeon S, Han S, Lee J, et al. Population pharmacokinetic analysis of piperacillin in burn patients. Antimicrob Agents Chemother. 2014 Jul;58(7):3744–3751.
   PubMed Web of Science ®Google Scholar
• Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, et al. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. J Antimicrob Chemother. 2014 Jan;69(1):180–189.
   PubMed Web of Science ®Google Scholar
• Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother. 2005 Aug;56(2):388–395.
   PubMed Web of Science ®Google Scholar
• Soto E, Shoji S, Muto C, et al. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. Br J Clin Pharmacol. 2014 Mar;77(3):509–521.
   PubMed Web of Science ®Google Scholar
• Wilkes S, van Berlo I, Ten Oever J, et al. Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen. Int J Antimicrob Agents. 2019 Mar;53(3):310–317.
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother. 2010 Aug;65(8):1771–1778.
   PubMed Web of Science ®Google Scholar
• Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia. 2020;12(1):11. doi: 10.1186/s41479-020-00074-3
   Web of Science ®Google Scholar
• Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014 Oct 23;371(17):1619–1628. doi: 10.1056/NEJMra1312885
   PubMed Web of Science ®Google Scholar
• Tan SJ, Cockcroft M, Page-Sharp M, et al. Population pharmacokinetic study of ceftriaxone in elderly patients, using cystatin C-Based estimates of renal function to account for frailty. Antimicrobial agents and chemotherapy. Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00874-20
   Google Scholar
• Simon N, Dussol B, Sampol E, et al. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin Pharmacokinet. 2006;45(5):493–501. doi: 10.2165/00003088-200645050-00004
   PubMed Web of Science ®Google Scholar
• Dreesen E, Gijsen M, Elkayal O, et al. Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia. J Antimicrob Chemother. 2022 Aug 25;77(9):2479–2488. doi: 10.1093/jac/dkac209
   PubMed Web of Science ®Google Scholar
• Bos JC, Prins JM, Mistício MC, et al. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-saharan African patients: a population pharmacokinetic modelling study. J Antimicrob Chemother. 2018 Jun 1;73(6):1620–1629. doi: 10.1093/jac/dky071
   PubMed Web of Science ®Google Scholar
• Leegwater E, Kraaijenbrink BVC, Moes D, et al. Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients. J Antimicrob Chemother. 2020 Jun 1;75(6):1554–1558. doi: 10.1093/jac/dkaa067
   PubMed Web of Science ®Google Scholar
• Roelofsen EE, Abdulla A, Muller AE, et al. Dose optimization of cefotaxime as pre-emptive treatment in critically ill adult patients: a population pharmacokinetic study. Brit J Clin Pharma. 2023 Feb;89(2):705–713.
   PubMed Web of Science ®Google Scholar
• Swartling M, Smekal AK, Furebring M, et al. Population pharmacokinetics of cefotaxime in intensive care patients. Eur J Clin Pharmacol. 2022 Feb;78(2):251–258.
   PubMed Web of Science ®Google Scholar
• Urien S, Laurent N, Barre J, et al. Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime—a population study in 25 elderly patients. Eur J Clin Pharmacol. 2004 Mar;60(1):11–16.
   PubMed Web of Science ®Google Scholar
• Lanoiselée J, Chaux R, Hodin S, et al. Population pharmacokinetic model of cefazolin in total hip arthroplasty. Sci Rep. 2021 Oct 5;11(1):19763. doi: 10.1038/s41598-021-99162-7
   PubMed Web of Science ®Google Scholar
• Naik BI, Roger C, Ikeda K, et al. Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. Br J Anaesth. 2017 Jun 1;118(6):876–882. doi: 10.1093/bja/aex026
   PubMed Web of Science ®Google Scholar
• Lanckohr C, Horn D, Voeller S, et al. Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. J Thorac Cardiovasc Surg. 2016 Aug;152(2):603–610.
   PubMed Web of Science ®Google Scholar
• Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009 Apr;53(4):1476–1481.
   PubMed Web of Science ®Google Scholar
• Breilh D, Saux MC, Delaisement C, et al. Pharmacokinetic population study to describe cefepime lung concentrations. Pulm Pharmacol Ther. 2001;14(2):69–74. doi: 10.1006/pupt.2000.0269
   PubMed Web of Science ®Google Scholar
• Chauzy A, Gregoire N, Ferrandière M, et al. Population pharmacokinetic/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance. J Antimicrob Chemother. 2022 Oct 28;77(11):3173–3179. doi: 10.1093/jac/dkac299
   PubMed Web of Science ®Google Scholar
• Kang S, Jang JY, Hahn J, et al. Dose optimization of cefpirome based on Population pharmacokinetics and target attainment during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2020 Apr 21;64(5): doi: 10.1128/AAC.00249-20
   Web of Science ®Google Scholar
• Alqahtani SA, Alsultan AS, Alqattan HM, et al. Population pharmacokinetic model-based evaluation of standard dosing regimens for cefuroxime used in coronary artery bypass graft surgery with cardiopulmonary bypass. Antimicrob Agents Chemother. 2018 Apr;62(4): doi: 10.1128/AAC.02241-17
   Web of Science ®Google Scholar
• Carlier M, Noë M, Roberts JA, et al. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. J Antimicrob Chemother. 2014 Oct;69(10):2797–2803.
   PubMed Web of Science ®Google Scholar
• Conil JM, Georges B, Ravat F, et al. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Clin Ther. 2013 Oct;35(10):1603–1612.
   PubMed Web of Science ®Google Scholar
• Georges B, Conil JM, Seguin T, et al. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob Agents Chemother. 2009 Oct;53(10):4483–4489.
   PubMed Web of Science ®Google Scholar
• Conil JM, Georges B, Lavit M, et al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Brit J Clin Pharma. 2007 Jul;64(1):27–35.
   PubMed Web of Science ®Google Scholar
• Isla A, Trocóniz IF, de Tejada IL, et al. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol. 2012 May;68(5):735–745.
   PubMed Web of Science ®Google Scholar
• Fish DN. Levofloxacin: update and perspectives on one of the original ‘respiratory quinolones’. Expert review of anti-infective therapy. Exp Rev Anti-Infective Ther. 2003 Oct;1(3):371–387. doi: 10.1586/14787210.1.3.371
   PubMedGoogle Scholar
• Cojutti PG, Ramos-Martin V, Schiavon I, et al. Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function. Antimicrob Agents Chemother. 2017 Mar;61(3): doi: 10.1128/AAC.02134-16
   Web of Science ®Google Scholar
• Setiawan E, Abdul-Aziz MH, Cotta MO, et al. Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients. Sci Rep. 2022 May 27;12(1):8930. doi: 10.1038/s41598-022-12627-1
   PubMed Web of Science ®Google Scholar
• Kiem S, Ryu SM, Lee YM, et al. Population pharmacokinetics of levofloxacin in Korean patients. J Chemother. 2016 Aug;28(4):308–313. doi: 10.1179/1973947815Y.0000000033
   PubMed Web of Science ®Google Scholar
• Eloy G, Lebeaux D, Launay M, et al. Influence of renal function and age on the pharmacokinetics of levofloxacin in patients with bone and joint infections. Antibiotics (Basel, Switzerland). 2020 Jul 10;9(7):401. doi: 10.3390/antibiotics9070401
   PubMed Web of Science ®Google Scholar
• Deguchi T, Nakane K, Yasuda M, et al. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents. 2010 Jun;35(6):573–577.
   PubMed Web of Science ®Google Scholar
• Collignon PJ, Conly JM, Andremont A, et al. World Health organization ranking of antimicrobials according to their importance in human Medicine: a critical step for developing risk management strategies to control Antimicrobial resistance from food animal production. Clin Infect Dis. 2016 Oct 15;63(8):1087–1093. doi: 10.1093/cid/ciw475
   PubMed Web of Science ®Google Scholar
• Cios A, Wyska E, Szymura-Oleksiak J, et al. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol. 2014 Sep;57:107–113.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Alobaid AS, Wallis SC, et al. Defining optimal dosing of ciprofloxacin in patients with septic shock. J Antimicrob Chemother. 2019 Jun 1;74(6):1662–1669. doi: 10.1093/jac/dkz069
   PubMed Web of Science ®Google Scholar
• Khachman D, Conil JM, Georges B, et al. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. J Antimicrob Chemother. 2011 Aug;66(8):1798–1809.
   PubMed Web of Science ®Google Scholar
• Abdulla A, Rogouti O, Hunfeld NGM, et al. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. Eur J Clin Pharmacol. 2020 Jul;76(7):957–967.
   PubMed Web of Science ®Google Scholar
• Roger C, Wallis SC, Louart B, et al. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. J Antimicrob Chemother. 2016 Jun;71(6):1643–1650.
   PubMed Web of Science ®Google Scholar
• Anzueto A, Niederman MS, Pearle J, et al. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis. 2006 Jan 1;42(1):73–81. doi: 10.1086/498520
   PubMed Web of Science ®Google Scholar
• Fogarty C, Torres A, Choudhri S, et al. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia. Int J Clin Pract. 2005 Nov;59(11):1253–1259.
   PubMed Web of Science ®Google Scholar
• Ito F, Ohno Y, Toyoshi S, et al. Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection. Ther Adv Respir Dis. 2016 Feb;10(1):34–42.
   PubMed Web of Science ®Google Scholar
• Wicha SG, Haak T, Zink K, et al. Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. J Clin Pharmacol. 2015 Jun;55(6):639–646.
   PubMed Web of Science ®Google Scholar
• Kees MG, Schaeftlein A, Haeberle HA, et al. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. J Antimicrob Chemother. 2013 Jun;68(6):1331–1337.
   PubMed Web of Science ®Google Scholar
• Fraisse T, Gras Aygon C, Paccalin M, et al. Aminoglycosides use in patients over 75 years old. Age Ageing. 2014 Sep;43(5):676–681.
   PubMed Web of Science ®Google Scholar
• Medellín-Garibay SE, Romano-Aguilar M, Parada A, et al. Amikacin pharmacokinetics in elderly patients with severe infections. Eur J Pharm Sci. 2022 Aug 1;175:106219. doi: 10.1016/j.ejps.2022.106219
   PubMed Web of Science ®Google Scholar
• Kato H, Parker SL, Roberts JA, et al. Population pharmacokinetics analysis of amikacin Initial dosing regimen in elderly patients. Antibiotics (Basel, Switzerland). 2021 Jan 20;10(2):100. doi: 10.3390/antibiotics10020100
   PubMed Web of Science ®Google Scholar
• Roger C, Wallis SC, Muller L, et al. Influence of renal replacement modalities on amikacin Population pharmacokinetics in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother. 2016 Aug;60(8):4901–4909.
   PubMed Web of Science ®Google Scholar
• Carrié C, Delzor F, Roure S, et al. Population pharmacokinetic study of the Suitability of standard dosing regimens of amikacin in critically ill patients with open-abdomen and negative-pressure wound therapy. Antimicrob Agents Chemother. 2020 Mar 24;64(4): doi: 10.1128/AAC.02098-19
   PubMed Web of Science ®Google Scholar
• Tabah A, Lipman J, Roberts JA. Are new gentamicin dosing guidelines suitable for achieving target concentrations in patients with sepsis and septic shock? Anaesth Crit Care Pain Med. 2016 Oct;35(5):311–312. doi: 10.1016/j.accpm.2016.08.002
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Crapis M, et al. Gentamicin once-daily in enterococcal endocarditis. Int J Cardiol. 2013 Oct 12;168(5):5033–5034. doi: 10.1016/j.ijcard.2013.07.225
   PubMed Web of Science ®Google Scholar
• Charhon N, Neely MN, Bourguignon L, et al. Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients. Antimicrob Agents Chemother. 2012 Apr;56(4):1862–1869.
   PubMed Web of Science ®Google Scholar
• Bos JC, Prins JM, Mistício MC, et al. Population pharmacokinetics with Monte Carlo simulations of gentamicin in a Population of severely ill adult patients from sub-Saharan Africa. Antimicrob Agents Chemother. 2019 Apr;63(4): doi: 10.1128/AAC.02328-18
   PubMed Web of Science ®Google Scholar
• Roberts JA, Field J, Visser A, et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother. 2010 Sep;54(9):3635–3640.
   PubMed Web of Science ®Google Scholar
• Teigen MM, Duffull S, Dang L, et al. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol. 2006 Nov;46(11):1259–1267.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Taccetti G, Burgel PR, et al. Tobramycin safety and efficacy review article. Respir med. 2022 Apr;195:106778.
   PubMed Web of Science ®Google Scholar
• Koloskoff K, Thirion DJG, Matouk E, et al. New recommendations of a height-based dosing regimen of Tobramycin for cystic fibrosis in adults: a population pharmacokinetic analysis. Ther Drug Monit. 2023 Apr 1;45(2):251–258. doi: 10.1097/FTD.0000000000001021
   PubMed Web of Science ®Google Scholar
• Hennig S, Standing JF, Staatz CE, et al. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clin Pharmacokinet. 2013 Apr;52(4):289–301.
   PubMed Web of Science ®Google Scholar
• Conil JM, Georges B, Ruiz S, et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Brit J Clin Pharma. 2011 Jan;71(1):61–71.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1459–1470. doi: 10.1517/17425255.2011.623126
   PubMed Web of Science ®Google Scholar
• Bastida C, Hernández-Tejero M, Cariqueo M, et al. Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections. J Antimicrob Chemother. 2022 Apr 27;77(5):1365–1371. doi: 10.1093/jac/dkac036
   PubMed Web of Science ®Google Scholar
• Broeker A, Wicha SG, Dorn C, et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. Crit Care. 2018 Dec 17;22(1):341. doi: 10.1186/s13054-018-2278-4
   PubMed Web of Science ®Google Scholar
• Borsuk-De Moor A, Rypulak E, Potręć B, et al. Population pharmacokinetics of high-dose tigecycline in patients with sepsis or septic shock. Antimicrob Agents Chemother. 2018 Apr;62(4): doi: 10.1128/AAC.02273-17
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother. 2008 Sep;62(Suppl 1):i11–6. doi: 10.1093/jac/dkn242
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005 Jan;49(1):220–229.
   PubMed Web of Science ®Google Scholar
• Morata L, Tornero E, Martínez-Pastor JC, et al. Clinical experience with linezolid for the treatment of orthopaedic implant infections. J Antimicrob Chemother. 2014 Sep;69(Suppl 1):i47–52.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Hashimoto W, Taniguchi S, et al. Pharmacokinetics of linezolid in the mediastinum and pleural space. Int J Infect Dis. 2013 Nov;17(11):e1060–1.
   PubMed Web of Science ®Google Scholar
• Pai MP, Cojutti PG, Gerussi V, et al. Linezolid Population pharmacokinetics to improve dosing in cardiosurgical patients: factoring a New drug–drug interaction pathway. Clin Infect Dis. 2023 Apr 3;76(7):1173–1179. doi: 10.1093/cid/ciac917
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Yao F, et al. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study. Drug Design Develop Therapy. 2021;15:2129–2141. doi: 10.2147/DDDT.S303497
   PubMed Web of Science ®Google Scholar
• Roger C, Muller L, Wallis SC, et al. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2016 Feb;71(2):464–470.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Yukawa E, Hiraki Y, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J Clin Pharmacol. 2013 Sep;53(9):967–973.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother. 2011 May;55(5):1867–1873.
   PubMed Web of Science ®Google Scholar
• Courjon J, Demonchy E, Cua E, et al. Efficacy and safety of clindamycin-based treatment for bone and joint infections: a cohort study. Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2513–2518.
   PubMed Web of Science ®Google Scholar
• Bouazza N, Pestre V, Jullien V, et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Brit J Clin Pharma. 2012 Dec;74(6):971–977.
   PubMed Web of Science ®Google Scholar
• Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs. 2007;67(10):1483–1512. doi: 10.2165/00003495-200767100-00008
   PubMed Web of Science ®Google Scholar
• Samura M, Takada K, Yamamoto R, et al. Population pharmacokinetic analysis and dosing optimization based on unbound Daptomycin concentration and cystatin C in nonobese elderly patients with hypoalbuminemia and Chronic kidney disease. Pharm Res. 2021 Jun;38(6):1041–1055.
   PubMed Web of Science ®Google Scholar
• Grégoire N, Marchand S, Ferrandière M, et al. Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. J Antimicrob Chemother. 2019 Jan 1;74(1):117–125. doi: 10.1093/jac/dky374
   PubMed Web of Science ®Google Scholar
• Soraluce A, Asín-Prieto E, Rodríguez-Gascón A, et al. Population pharmacokinetics of daptomycin in critically ill patients. Int J Antimicrob Agents. 2018 Aug;52(2):158–165.
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Tascini C, Polillo M, et al. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents. 2013 Sep;42(3):250–255.
   PubMed Web of Science ®Google Scholar
• Castañeda-García A, Blázquez J, Rodríguez-Rojas A. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics(Basel, Switzerland). 2013 Apr 16;2(2):217–236. doi: 10.3390/antibiotics2020217
   PubMedGoogle Scholar
• Merino-Bohórquez V, Docobo-Pérez F, Sojo J, et al. Population pharmacokinetics and pharmacodynamics of fosfomycin in non–critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. Clin Microbiol Infect. 2018 Nov;24(11):1177–1183.
   PubMed Web of Science ®Google Scholar
• Parker SL, Frantzeskaki F, Wallis SC, et al. Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. Antimicrob Agents Chemother. 2015 Oct;59(10):6471–6476.
   PubMed Web of Science ®Google Scholar
• Proietti M, Cesari M. Frailty: what is it? Advances in experimental medicine and biology. Adv Exp Med Bio. 2020;1216:1–7.
   PubMedGoogle Scholar
• Dent E, Martin FC, Bergman H, et al. Management of frailty: opportunities, challenges, and future directions. Lancet (London, England). 2019 Oct 12;394(10206):1376–1386. doi: 10.1016/S0140-6736(19)31785-4
   PubMed Web of Science ®Google Scholar
• Sanz-Codina M, Wicha SG, Wulkersdorfer B, et al. Comparison of ultrafiltration and microdialysis for ceftriaxone protein-binding determination. J Antimicrob Chemother. 2023 Feb 1;78(2):380–388. doi: 10.1093/jac/dkac400
   PubMed Web of Science ®Google Scholar